Mechanism of action of antidepressant medications

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 4, 1999, Pages 4-13

  Feighner, John P ^a,b  

^a John P Feighner MD Inc   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DEXFENFLURAMINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; RESERPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VALPROIC ACID; VENLAFAXINE;

CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FOOD DRUG INTERACTION; HUMAN; HYPERTENSION; OBESITY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUSTAINED RELEASE PREPARATION; VERTIGO; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DOWN-REGULATION; HISTORY, 20TH CENTURY; HUMANS; MONOAMINE OXIDASE INHIBITORS; RECEPTORS, ADRENERGIC; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, DOPAMINE; RECEPTORS, GLUCOCORTICOID; RECEPTORS, SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0033002399     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Schatzberg AF, DeBattista C, Ereshefsky L, et al. Current psychotropic dosing and monitoring guidelines. Prim Psychiatry 1997:35-61
2. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-522
3. Lapin IP, Oxenkrug GF. Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect. Lancet 1969;1: 132-136
4. Kuhn R. The treatment of depressive states with G22355 (imipramine hydrochloride). Am J Psychiatry 1958;115:459-464
5. Lehmann HE, Kline NS. Clinical discoveries with antidepressant drugs. In: Parnham MJ, Bruinvels J, eds. Discoveries in Pharmacology, vol 1. Amsterdam, the Netherlands: Elsevier; 1983:209-221
6. Taboulet P, Michard F, Muszynski J, et al. Cardiovascular repercussions of seizures during cyclic antidepressant poisoning. Clin Toxicol 1995;33: 205-211
7. DeToledo JC, Haddad H, Ramsay RE. Status epilepticus associated with the combination of valproic acid and clomipramine. Ther Drug Monit 1996;19:71-73
8. Brodkin ES, McDougle CJ, Cohen DJ, et al. Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. J Child Adolesc Psychopharmacol 1997;7:109-121
9. Olfson M, Klerman GL. Trends in the prescription of antidepressants by office-based psychiatrists. Am J Psychiatry 1993;150:571-577
10. Gardner DM, Shulman KI, Walker SE, et al. The making of a user friendly MAOI diet. J Clin Psychiatry 1996;57:99-104
11. Montgomery SA, McAuley R, Rani SJ, et al. A double-blind comparison of zimelidine and amitriptyline in endogenous depression. Acta Psychiatr Scand 1981;63(suppl 290):314-327
12. Pincus HA, Tanielian TL, Marcus SC. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialities. JAMA 1998;279:526-531
13. Leonard HL. New developments in the treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(suppl 14):39-45
14. Oehrberg S, Cristiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-379
15. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995; 152:1368-1371
16. Davidson JRT. Pharmacotherapy of social anxiety disorder. J Clin Psychiatry 1998;59:47-53
17. Marcus MD, Wing RR, Ewing L, et al. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry 1990;147:876-881
18. Hudson JI, McElroy SL, Raymond NC, et al. Fluvoxamine treatment of binge eating disorder: a multicenter, placebo-controlled trial. In: New Research Program and Abstracts of the 147th Annual Meeting of the American Psychiatric Association; May 26, 1994; Philadelphia, Pa. Abstract NR620:218
19. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study. N Engl J Med 1995;332:1529-1534
20. Jönsson B, Bebbington PE. What price depresssion? the cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164:665-673
21. Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J Clin Psychiatry 1998;59:279-288
22. Fava M, Rappe SM, Pava JA, et al. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry 1995;56:52-55
23. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 1997;11:S33-S37
24. Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1995;30:57-71
25. Clerc GE, Ruimy P, Verdeau-Pailles J, on behalf of the Venlafaxine French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-143
26. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-458
27. Derivan A, Entsuah AR, Kikta D. Venlafaxine: measuring the onset of antidepressant action. Psychopharmacol Bull 1995;31:439-447
28. Quitkin FM, Rabkin JK, Ross D, et al. Identification of true drug response to antidepressants. Arch Gen Psychiatry 1984;41:782-786
29. Quitkin FM, Rabkin JD, Markowitz JM. et al. Use of pattern analysis to identify true drug response. Arch Gen Psychiatry 1987;44:259-264
30. Benkert O, Gründer G, Wetzel H, et al. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 1998; 30:441-451
31. Gründer G, Wetzel H, Schlößer R, et al. Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24-hour monitoring. Pharmacopsychiatry 1996;29:72-78
32. Mahapatra SN, Hackett D. A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Int J Clin Pract 1997;51:209-213
33. Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995;56:574-579
34. Augustin BG, Cold JA, Jann MW. Venlafaxine and nefazodone, two pharmacologically distinct antidepressants. Pharmacotherapy 1997;17: 511-530
35. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16(suppl 2):37S-53S
36. Khan A, Rudolph R, Baumel B, et al. Venlafaxine in depressed geriatric outpatients: an open-label study. Psychopharmacol Bull 1995;31:753-758
37. Rudolph RL, Derivan AT, for the Venlafaxine XR 211 Study Group. Double-blind, placebo-controlled study of once-daily venlafaxine XR and fluoxetine in depressed outpatients. In: Scientific Abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology; December 8-12, 1997; Kamuela, Hawaii. page 173
38. Haskins T, Rudolph R, Pallay A, et al, for the Venlafaxine XR 210 Study Group. Double-blind, placebo-controlled study of once daily venlafaxine XR in outpatients with generalized anxiety disorder (GAD). In: Scientific Abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology; December 8-12, 1997; Kamuela, Hawaii. page 173
39. Preskorn SH. Selection of an antidepressant: mirtazapine. J Clin Psychiatry 1997;58(suppl 6):3-8
40. Stimmel GL, Depheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997;17: 10-21
41. Ascher JA, Cole JO, Colin J-N, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401
42. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337: 1195-1202
43. Taylor DP, Carter RB, Eison AS, et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 1995; 56(suppl 6):3-11
44. Davis R, Whittington R, Bryson HM. Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997;53:608-636
45. Stoudemire A. Expanding psychopharmacologic treatment options for the depressed medical patient. Psychosomatics 1995;36:S19-S26
46. Feighner J, Targum SD, Bennett ME, et al. A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. J Clin Psychiatry 1998;59:246-253
47. Vetulani J, Sulser F. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain [letter]. Nature 1975;257:495-496
48. Taylor SS, Buechler JA, Yonemoto W. cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu Rev Biochem 1990;59:971-1005
49. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996;16:2365-2372
50. Popoli M, Vocaturo C, Perez J, et al. Presynaptic Ca2+/calmodulin-dependent protein kinase II: autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin. Mol Pharmacol 1995; 48:623-629
51. Cleare AJ, Murray RM, O'Keane V. Do noradrenergic reuptake inhibitors affect serotonergic function in depression? Psychopharmacology 1997; 134:406-410
52. Mann JJ, Malone KM, Diehl DJ, et al. Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am J Psychiatry 1996;153:174-182
53. Geracioti T Jr, Loosen PT, Ekhator NN, et al. Uncoupling of serotonergic and noradrenergic systems in depression: preliminary evidence from continuous cerebrospinal fluid sampling. Depress Anxiety 1997;6:89-94